Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

Dendouga, Najoua; Fochesato, Michel; Lockman, Laurence; Mossman, Sally; Giannini, Sandra L.

doi:10.1016/j.vaccine.2012.01.088

Cited by 122 publications

(122 citation statements)

References 65 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…The Ags (clinical-grade) gE (19), Alexa Fluor 647-labeled gE, and the Adjuvant System AS01 were produced at GlaxoSmithKline. One human dose of AS01 contains 50 mg MPL (GlaxoSmithKline), 50 mg QS-21 (Antigenics, a wholly owned subsidiary of Agenus, Lexington, MA), and liposomes.…”

Section: Vaccine Formulationsmentioning

confidence: 99%

“…Anti-gE and anti-OVA Ab concentrations (in ELISA units per milliliter and defined by internal standards) were measured by ELISA, following a protocol described previously (19), with a minor addition: for the measurement of anti-OVA Ab concentrations, 96-well ELISA plates were coated with an overnight incubation at 4˚C of 10 mg/ml OVA in PBS.…”

Section: Ag-specific Ab and T Cell Responsementioning

confidence: 99%

“…AS01 is included in a number of candidate vaccines against infections such as those caused by Plasmodium falciparium (malaria) (17,18), varicella zoster virus reactivation (shingles) (19), HIV (20,21), and Mycobacterium tuberculosis (22) for which both Abs and T cell immunity are thought to be involved in protection. During the preclinical and clinical evaluations of these candidate vaccines, both Ag-specific Ab and CD4 + T cell responses have been consistently observed, suggesting that AS01 promotes these adaptive responses irrespective of the type of Ag used (2).…”

mentioning

confidence: 99%

“…Given the known immunostimulatory properties of the AS01 constituents liposome-based MPL and QS-21, the objective of this study was to describe, in mouse models, the early innate immune parameters induced by AS01 after immunization and to identify relationships between these parameters and the Ag-specific Ab and T cell responses raised against two model Ags, glycoprotein E [gE from varicella zoster virus (19)] and OVA.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

Didierlaurent

Collignon

Bourguignon

et al. 2014

The Journal of Immunology

Self Cite

219

198

View full text Add to dashboard Cite

Adjuvant System AS01 is a liposome-based vaccine adjuvant containing 3-O-desacyl-4′-monophosphoryl lipid A and the saponin QS-21. AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III). Given the known immunostimulatory properties of MPL and QS-21, the objective of this study was to describe the early immune response parameters after immunization with an AS01-adjuvanted vaccine and to identify relationships with the vaccine-specific adaptive immune response. Cytokine production and innate immune cell recruitment occurred rapidly and transiently at the muscle injection site and draining lymph node postinjection, consistent with the rapid drainage of the vaccine components to the draining lymph node. The induction of Ag-specific Ab and T cell responses was dependent on the Ag being injected at the same time or within 24 h after AS01, suggesting that the early events occurring postinjection were required for these elevated adaptive responses. In the draining lymph node, after 24 h, the numbers of activated and Ag-loaded monocytes and MHCIIhigh dendritic cells were higher after the injection of the AS01-adjuvanted vaccine than after Ag alone. However, only MHCIIhigh dendritic cells appeared efficient at and necessary for direct Ag presentation to T cells. These data suggest that the ability of AS01 to improve adaptive immune responses, as has been demonstrated in clinical trials, is linked to a transient stimulation of the innate immune system leading to the generation of high number of efficient Ag-presenting dendritic cells.

show abstract

Section: Vaccine Formulationsmentioning

confidence: 99%

Section: Ag-specific Ab and T Cell Responsementioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

Didierlaurent

Collignon

Bourguignon

et al. 2014

The Journal of Immunology

Self Cite

219

198

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that the glycoprotein E (gE) antigen is one of the most promising candidate antigen markers (2,3). gE is one of the most important protective antigens in VZV, and since it is capable of inducing cellular and humoral immunity, gE is considered the most appropriate candidate antigen for a DNA vaccine (4).…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Wei

Gan

Ren

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. In the present study a eukaryotic expression vector of varicella zoster virus (VZV) glycoprotein E (gE) was constructed and enabled to express in COS7 cells. Furthermore, a specific immune response against the VZV gE eukaryotic expression plasmid was induced in BALB/c mice. The VZV gE gene was amplified using polymerase chain reaction (PCR) and cloned into a eukaryotic expression vector, pcDNA3.1. The recombinant vector was subsequently transfected into COS7 cells using a liposome transfection reagent. The recombinant protein was instantaneously expressed by the transfected cells, as detected by immunohistochemistry, and the recombinant pcDNA-VZV gE plasmid was subsequently used to immunize mice. Tissue expression levels were analyzed by reverse transcription-PCR. In addition, the levels of serum antibodies and spleen lymphocyte proliferation activity were investigated. The amplified target gene included the full-length gE gene (~2.7 kb), and the recombinant expression vector induced gE expression in COS7 cells. In addition, the expression plasmid induced sustained expression in vivo following immunization of mice. Furthermore, the plasmid was capable of inducing specific antibody production and effectively stimulating T cell proliferation. Effective humoral and cellular immunity was triggered in the mice immunized with the VZV gE eukaryotic expression vector. The results of the present study laid the foundation for future research into a VZV DNA vaccine.

show abstract

Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease

Wang,

Wang

2024

Biotechnology Journal

View full text Add to dashboard Cite

A vaccine is a biological preparation that contains the antigen capable of stimulating the immune system to form the defense against pathogens. Vaccine development often confronts big challenges, including time/energy‐consuming, low efficacy, lag to pathogen emergence and mutation, and even safety concern. However, these seem now mostly conquerable through constructing the advanced translational platforms that can make innovative vaccines, sometimes, potentiated with a distinct multifunctional VADS (vaccine adjuvant delivery system), as evidenced by the development of various vaccines against the covid‐19 pandemic at warp speed. Particularly, several covid‐19 vaccines, such as the viral‐vectored vaccines, mRNA vaccines and DNA vaccines, regarded as the innovative ones that are rapidly made via the high technology‐based translational platforms. These products have manifested powerful efficacy while showing no unacceptable safety profile in clinics, allowing them to be approved for massive vaccination at also warp speed. Now, the proprietary translational platforms integrated with the state‐of‐the‐art biotechnologies, and even the artificial intelligence (AI), represent an efficient mode for rapid making innovative clinical vaccines against infections, thus increasingly attracting interests of vaccine research and development. Herein, the advanced translational platforms for making innovative vaccines, together with their design principles and immunostimulatory efficacies, are comprehensively elaborated.

show abstract

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

Cited by 122 publications

References 65 publications

Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease

Contact Info

Product

Resources

About